Obesity drug from Zealand shows potential in early trial [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
four months, results the company said support further research on a medicine it hopes could compete with drugs from Novo Nordisk and Eli Lilly. The shot, called petrelintide, is part of a class of drugs called amylin analogues that work differently than GLP-1 agonists like Novo's Wegovy or Lilly's Zepbound. They may also be useful in combination to spur greater weight loss. The data Zealand disclosed Thursday come from the second part of a Phase 1 trial meant to determine the best dose to advance into the larger studies that might support an approval application. This portion of the trial enrolled 48 people with a body mass index of 29 or higher, and randomized 36 to take one of three weekly doses of petrelintide. The other 12 received a placebo shot. Zealand only disclosed data from participants given the highest dose, who lost on average 8.6% of their body weight, and those on placebo, who lost an average of 1.7%. The company expects to release more data at an upcoming medical
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- WeightWatchers CEO Sima Sistani is leaving the company [Yahoo! Finance]Yahoo! Finance
- PFE vs. NVO: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's Wegovy-Fueled Gains Fading as Analyst Doubts Grow [Yahoo! Finance]Yahoo! Finance
- She took Ozempic, now she can't eat without vomiting. Lawsuit claims the drug made her ill [USA TODAY]USA TODAY
- Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/16/24 - Form 6-K
- NVO's page on the SEC website